Fibromyalgia Treatment Market Global Industry Insights, 2026

Fibromyalgia is a common and complex chronic pain disorder that causes musculoskeletal pain, fatigue and localized tenderness affecting individuals mentally, physically and socially. Fibromyalgia is mainly caused due to genetic conditions, however actual cause is still unknown. The most common symptoms of fibromyalgia are fatigue, sleeping problems, chronic muscle pain and tender points. An individual with fibromyalgia can also have symptoms such as headaches, poor concentration and depression. Fibromyalgia symptoms can be gradually accumulated with the time or it can be done by some external factors. Fibromyalgia treatments include therapy, medications, regular aerobic exercise, stress reduction, and others. Furthermore, for treatment of Fibromyalgia antidepressants or pain medication are prescribed to treat depression, anxiety, pain, and fatigue.

Request a sample copy of this report @ https://www.coherentmarketinsights.com/insight/request-sample/1691

Fibromyalgia Treatment Market: Market Dynamics

Increasing prevalence of Fibromyalgia is expected to augment market growth. According to National Fibromyalgia and Chronic Pain Association, 2014, an estimated 210 million people in 2015, were affected with fibromyalgia syndrome, accounting for 2-4% of the total world population. Moreover, growth of the market is driven by increasing clinical trials by the manufacturers and research organizations and launch of novel diagnostics in order to reduce the burden of the disease with early and accurate disease diagnosis. For instance, in 2013, Innovative Med Concepts, LLC initiated the clinical trial for the drug candidate IMC-1, for the treatment of patients with fibromyalgia. Also, in March 2018, IQuity, a data science company launched a new blood test called Isolate Fibromyalgia, which uses RNA gene expression analysis to detect fibromyalgia, thus aiding in efficient diagnostics, which can provide early medical intervention.